98%
921
2 minutes
20
Background: Single-session stereotactic radiosurgery (SRS) is a proven and effective treatment modality for various benign, malignant, and functional intra-cranial pathologies. In certain situations, single-fraction SRS is limited because of lesion size and location. Hypo-fractionated gamma knife radiosurgery (hfGKRS) is an alternative approach for such unconventional indications.
Objective: To evaluate the feasibility, efficacy, safety, and complication profile of hfGKRS with evaluation of different fractionation schemes and dosing patterns.
Methodology: The authors prospectively evaluated 202 patients treated with frame-based hfGKRS over a 9-year period. GKRS was administered fractionated because of either a large volume (>14 cc) or an inability to spare neighboring organs at risk from permissible radiation in single-session GKRS. The inter-fraction interval was kept at 24 hours, and the dose calculation was performed with linear quadratic equations. Patients with more than 3 years of clinical and radiological follow-up were included in prospective analysis. At pre-decided follow-up criteria, treatment effects and side effects were documented on objective scales.
Results: A total of 169/202 patients met inclusion criteria. 41% patients received treatment in three fractions, whereas 59% received two-fraction GKRS. Two patients of giant cavernous sinus hemangiomas were treated with 5 Gy in the five-fraction regimen. In patients with more than 3 years of follow-up, the obliteration rate was 88% for complex arteriovenous malformations (AVMs) treated with hfGKRS because of eloquent locations, whereas it was 62% for Spetzler-Martin grade 4-5 AVMs. For non-AVM pathologies (meningiomas, schwannomas, pituitary adenomas, paragangliomas, hypothalamic hamartomas, etc.), the 5-year progression free survival was 95%. Tumor failure was noted in 0.05% patient population. Radiation necrosis developed in 8.1% patients, and radiation-induced brain edema developed in 12% patients. It was resistant to treatment in 4% patients. No patient developed radiation-induced malignancy. Hypo-fractionation did not provide any hearing improvement in giant vestibular schwannomas.
Conclusion: hfGKRS is a valuable standalone treatment option for candidates unsuitable for single-session GKRS. The dosing parameters need to be tailored as per the pathology and neighboring structures. It provides comparable results to single-session GKRS with an acceptable safety and complication profile.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/0028-3886.373638 | DOI Listing |
Curr Cardiol Rep
September 2025
Division of Cardiology, Health Sciences Building, University of Washington Medical Center, 1959 NE Pacific StreetSuite #A506D Box 356422, Seattle, WA, 98195, USA.
Purpose Of Review: Patients living with cancer are at risk for significant potential cardiovascular complications as a direct result of cancer treatment or due to underlying comorbid cardiovascular disease. This article reviews the methods of risk stratification as well as pharmacologic and nonpharmacologic approaches to cardioprotection in cardio-oncology.
Recent Findings: Several cancer-specific risk stratification tools have incorporated variables such as age, sex, cancer subtype, traditional cardiovascular risk factors and cancer treatment-related parameters to assess cardiovascular specific risk prior to cancer therapy.
Arch Gynecol Obstet
September 2025
Department of Obstetrics and Gynaecology, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy.
Objectives: Recommendations regarding the use of third-trimester ultrasound lack universal consensus. Yet, there is evidence which supports its value in assessing fetal growth, fetal well-being, and a number of pregnancy-related complications. This literature review evaluates the available scientific evidence regarding its applications, usefulness, and the timing of the third-trimester scan in a low-risk population.
View Article and Find Full Text PDFCancer Epidemiol Biomarkers Prev
September 2025
University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, United States.
Background: Comorbidities may affect incidence and management of cancers. The burden of comorbidities among AIAN cancer patients and survivors is unknown.
Methods: Using SEER-Medicare, we identified AIAN people aged 66+ years diagnosed with female breast, lung, and colorectal cancers (2000-2019), with at least one year of Medicare coverage prior to diagnosis.
Kaohsiung J Med Sci
September 2025
Hepatitis Research Center, College of Medicine; Center for Metabolic Disorders and Obesity; Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver condition that can progress to severe complications such as metabolic dysfunction-associated steatohepatitis (MASH). Despite its growing burden, there are no reliable non-invasive biomarkers for tracking disease progression. In this study, we established a murine MASLD/MASH model using a high-fat diet and chemical (CCl) induction.
View Article and Find Full Text PDFG Ital Nefrol
August 2025
Unit of Nephrology and Dialysis, Department of Medicine and Surgery, University of Enna "Kore", 94100, Enna, Italy.
Hyperkalemia is a common and serious complication in dialysis patients, with increased incidence and severity over time. Newer potassium binders, patiromer and sodium zirconium cyclosilicate (SZC), offer improved tolerability compared to older agents. This meta-analysis aims to evaluate the efficacy and safety of these newer binders in dialysis patients.
View Article and Find Full Text PDF